Cargando…

The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer

OBJECTIVE: Identifying new modifiable prognostic markers is important for ovarian cancer (OC). Low parasympathic activity is associated with inflammation, oxidative stress and sympathetic nervous system activation. Previous studies reported that low vagal nerve activity, measured by low heart rate v...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherifi, François, Lefevre Arbogast, Sophie, Font, Jonaz, Abdeddaim, Cyril, Becourt, Stephanie, Penel, Nicolas, Coquan, Elodie, Lequesne, Justine, Gidron, Yori, Joly, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745166/
https://www.ncbi.nlm.nih.gov/pubmed/36523968
http://dx.doi.org/10.3389/fonc.2022.1049970
_version_ 1784849088250904576
author Cherifi, François
Lefevre Arbogast, Sophie
Font, Jonaz
Abdeddaim, Cyril
Becourt, Stephanie
Penel, Nicolas
Coquan, Elodie
Lequesne, Justine
Gidron, Yori
Joly, Florence
author_facet Cherifi, François
Lefevre Arbogast, Sophie
Font, Jonaz
Abdeddaim, Cyril
Becourt, Stephanie
Penel, Nicolas
Coquan, Elodie
Lequesne, Justine
Gidron, Yori
Joly, Florence
author_sort Cherifi, François
collection PubMed
description OBJECTIVE: Identifying new modifiable prognostic markers is important for ovarian cancer (OC). Low parasympathic activity is associated with inflammation, oxidative stress and sympathetic nervous system activation. Previous studies reported that low vagal nerve activity, measured by low heart rate variability (HRV), may predict poor cancer prognosis. We aimed to examine the prognostic value of HRV in OC. METHODS: This bicentric retrospective study included patients diagnosed with serous OC FIGO stage ≥IIB, between January 2015 and August 2019, with electrocardiograms (ECG) available around diagnosis. HRV was measured from ECG using the time domain parameter of standard deviation of all normal-to-normal heartbeat intervals (SDNN). Optimal SDNN cut-off was determined using the Youden index criteria of time-dependent ROC curves. We used multivariate cox proportional hazard models to investigate the association between HRV and overall survival (OS), while adjusting for well-known OC prognostic factors. RESULTS: The 202 patients included were 65.7 years-old on average, 93% had stage FIGO IIIC/IV, 56% had complete surgical resection. Median OS was 38.6 months [95%CI:34.4-47.4]. The median SDNN was 11.1ms, with an optimal cut-off of 10ms to predict OS. OS was shorter for patients with low HRV compared to high HRV (26.4 vs 45.1 months; p<0.001). In multivariate analysis, HRV remained an independent prognostic factor with a two-fold higher risk of death among patients with low SDNN compared to those with high SDNN (HR=2.03, 95%CI=1.35-3.06, p<0.001). CONCLUSION: Low HRV, was associated with worse OS in OC patients, supporting previous studies on the prognostic role of HRV in cancer. If replicated in prospective studies, vagal nerve activity may be a new therapeutic target in OC.
format Online
Article
Text
id pubmed-9745166
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97451662022-12-14 The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer Cherifi, François Lefevre Arbogast, Sophie Font, Jonaz Abdeddaim, Cyril Becourt, Stephanie Penel, Nicolas Coquan, Elodie Lequesne, Justine Gidron, Yori Joly, Florence Front Oncol Oncology OBJECTIVE: Identifying new modifiable prognostic markers is important for ovarian cancer (OC). Low parasympathic activity is associated with inflammation, oxidative stress and sympathetic nervous system activation. Previous studies reported that low vagal nerve activity, measured by low heart rate variability (HRV), may predict poor cancer prognosis. We aimed to examine the prognostic value of HRV in OC. METHODS: This bicentric retrospective study included patients diagnosed with serous OC FIGO stage ≥IIB, between January 2015 and August 2019, with electrocardiograms (ECG) available around diagnosis. HRV was measured from ECG using the time domain parameter of standard deviation of all normal-to-normal heartbeat intervals (SDNN). Optimal SDNN cut-off was determined using the Youden index criteria of time-dependent ROC curves. We used multivariate cox proportional hazard models to investigate the association between HRV and overall survival (OS), while adjusting for well-known OC prognostic factors. RESULTS: The 202 patients included were 65.7 years-old on average, 93% had stage FIGO IIIC/IV, 56% had complete surgical resection. Median OS was 38.6 months [95%CI:34.4-47.4]. The median SDNN was 11.1ms, with an optimal cut-off of 10ms to predict OS. OS was shorter for patients with low HRV compared to high HRV (26.4 vs 45.1 months; p<0.001). In multivariate analysis, HRV remained an independent prognostic factor with a two-fold higher risk of death among patients with low SDNN compared to those with high SDNN (HR=2.03, 95%CI=1.35-3.06, p<0.001). CONCLUSION: Low HRV, was associated with worse OS in OC patients, supporting previous studies on the prognostic role of HRV in cancer. If replicated in prospective studies, vagal nerve activity may be a new therapeutic target in OC. Frontiers Media S.A. 2022-11-29 /pmc/articles/PMC9745166/ /pubmed/36523968 http://dx.doi.org/10.3389/fonc.2022.1049970 Text en Copyright © 2022 Cherifi, Lefevre Arbogast, Font, Abdeddaim, Becourt, Penel, Coquan, Lequesne, Gidron and Joly https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Cherifi, François
Lefevre Arbogast, Sophie
Font, Jonaz
Abdeddaim, Cyril
Becourt, Stephanie
Penel, Nicolas
Coquan, Elodie
Lequesne, Justine
Gidron, Yori
Joly, Florence
The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer
title The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer
title_full The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer
title_fullStr The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer
title_full_unstemmed The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer
title_short The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer
title_sort promising prognostic value of vagal nerve activity at the initial management of ovarian cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745166/
https://www.ncbi.nlm.nih.gov/pubmed/36523968
http://dx.doi.org/10.3389/fonc.2022.1049970
work_keys_str_mv AT cherififrancois thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT lefevrearbogastsophie thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT fontjonaz thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT abdeddaimcyril thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT becourtstephanie thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT penelnicolas thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT coquanelodie thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT lequesnejustine thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT gidronyori thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT jolyflorence thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT cherififrancois promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT lefevrearbogastsophie promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT fontjonaz promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT abdeddaimcyril promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT becourtstephanie promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT penelnicolas promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT coquanelodie promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT lequesnejustine promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT gidronyori promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer
AT jolyflorence promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer